ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2025

NET LOSS PER SHARE

Summary of computation of basic and diluted net loss per share attributable to common shareholders


		Years Ended December 31,
		2025			2024
Numerator:
Net (loss) income		$	(39,719,147)		$	2,778,873
Denominator:
Weighted-average shares outstanding used in computing net (loss) income per share attributable to common shareholders, basic and diluted			1,756,844			1,036,799
Effect of potentially dilutive securities:
Warrants			—			20,882
Stock options			—			789
Diluted weighted-average common shares outstanding			1,756,844			1,058,469

Net (loss) income per share attributable to common shareholders, basic and diluted		$	(22.61)		$	2.68
Diluted net (loss) income per share attributable to common shareholders		$	(22.61)		$	2.63

Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net loss per share


		Year Ended
		December 31,
		2025		2024
Options issued and outstanding under stock option plan		180,827		142,978
Warrants		2,564,332		2,199,175
Deferred share units		42		42
Total		2,745,201		2,342,195